Adma Biologics (ADMA) Total Current Liabilities (2011 - 2025)

Adma Biologics' Total Current Liabilities history runs 14 years deep, the most recent figure standing at $69.5 million for Q4 2025.

• Quarterly Total Current Liabilities rose 25.2% year-over-year to $69.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $69.5 million (up 25.2% YoY) and the FY2025 annual result came in at $69.5 million, up 25.2% from the prior year.
• Total Current Liabilities was $69.5 million for Q4 2025 at Adma Biologics, up from $56.5 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $74.9 million in Q2 2025 and bottomed at $18.2 million in Q2 2021.
• A 5-year average of $43.4 million and a median of $43.1 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2021 — Total Current Liabilities jumped 96.3% — and 2023, when it declined 5.85%.
• Adma Biologics' Total Current Liabilities stood at $30.4 million in 2021, then gained by 29.26% to $39.3 million in 2022, then grew by 26.84% to $49.8 million in 2023, then climbed by 11.52% to $55.5 million in 2024, then increased by 25.2% to $69.5 million in 2025.
• Business Quant data shows ADMA's Total Current Liabilities at $69.5 million in Q4 2025, $56.5 million in Q3 2025, and $74.9 million in Q2 2025.